Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jan 8:2018:5308582.
doi: 10.1155/2018/5308582. eCollection 2018.

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Qixian Wang  1 , Min Long  1 , Hua Qu  1 , Rufei Shen  1 , Rui Zhang  1 , Jing Xu  1 , Xin Xiong  1 , Hui Wang  1 , Hongting Zheng  1
Affiliations
Meta-Analysis

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Qixian Wang et al. J Diabetes Res. .

Abstract

Objective: Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM). This study aims to review the outcomes of these existing studies and to discuss the therapeutic effects of DPP-4 inhibitors on T1DM.

Methods: We thoroughly searched the Medline, Embase, PubMed, and Cochrane Library databases and ClinicalTrials.gov for studies concerning the use of DPP-4 inhibitors in patients with T1DM.

Results: In preclinical trials, DPP-4 inhibitors improved the pathogenesis of T1DM. However, only a portion of the studies showed potential efficacy regarding clinical glycemic control and other clinical parameters. From this meta-analysis, pooled data from 5 randomized controlled trials revealed that the additional use of DPP-4 inhibitors resulted in a greater decrease in glycated hemoglobin A1c (HbA1c) levels (0.07%, 95% CI (-0.37%-0.23%)) than insulin monotherapy, although the decrease was not significant. A small decrease in postprandial glucose or insulin consumption was confirmed.

Conclusion: Although DPP-4 inhibitors may be beneficial for T1DM, existing studies do not strongly support these positive effects in clinical practice. Further optimized clinical trials are needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart illustrating the article screening process.
Figure 2
Figure 2
Risk of bias summary of included studies.
Figure 3
Figure 3
Forest plot of HbA1c.
See this image and copyright information in PMC

References

    1. American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33(Supplement 1):S11–S61. doi: 10.2337/dc10-S011. - DOI - PMC - PubMed
    1. Kim J. H., Lee C. G., Lee Y. A., Yang S. W., Shin C. H. Increasing incidence of type 1 diabetes among Korean children and adolescents: analysis of data from a nationwide registry in Korea. Pediatric Diabetes. 2016;17(7):519–524. doi: 10.1111/pedi.12324. - DOI - PubMed
    1. Gong C., Meng X., Jiang Y., Wang X., Cui H., Chen X. Trends in childhood type 1 diabetes mellitus incidence in Beijing from 1995 to 2010: a retrospective multicenter study based on hospitalization data. Diabetes Technology & Therapeutics. 2015;17(3):159–165. doi: 10.1089/dia.2014.0205. - DOI - PubMed
    1. Fazeli F. S., Souverein P. C., van der Vorst M. M., et al. Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. Pediatric Diabetes. 2016;17(1):44–52. doi: 10.1111/pedi.12232. - DOI - PubMed
    1. Lipman T. H., Levitt K. L., Ratcliffe S. J., et al. Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia Pediatric Diabetes Registry. Diabetes Care. 2013;36(6):1597–1603. doi: 10.2337/dc12-0767. - DOI - PMC - PubMed

MeSH terms